{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+G4+Related+Disease",
    "query": {
      "condition": "Immunoglobulin G4 Related Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunoglobulin+G4+Related+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T08:09:18.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02725476",
      "title": "Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgG4-RD"
      ],
      "interventions": [
        {
          "name": "XmAb5871",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-03",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725476"
    },
    {
      "nct_id": "NCT02616705",
      "title": "Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "IgG4-related Sclerosing Cholangitis",
        "IgG4-related Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 511,
      "start_date": "2015-11",
      "completion_date": "2019-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616705"
    },
    {
      "nct_id": "NCT05662241",
      "title": "A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "IgG4 Related Disease"
      ],
      "interventions": [
        {
          "name": "Obexelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Zenas BioPharma (USA), LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2023-01-09",
      "completion_date": "2029-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Naples, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662241"
    },
    {
      "nct_id": "NCT02422875",
      "title": "Comparative Autoantibody and Immunologic Cell Marker Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Lupus Erythematosus, Systemic",
        "Communicable Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2012-08",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422875"
    },
    {
      "nct_id": "NCT02705638",
      "title": "Treatment of IgG4-Related Disease With Revlimid and Rituximab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immunoglobulin G Subclass 4 Related Disease",
        "IgG4-related Disease",
        "Autoimmune Pancreatitis",
        "IgG4-related Sclerosing Cholangitis",
        "Retroperitoneal Fibrosis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2016-04",
      "completion_date": "2019-04",
      "has_results": false,
      "last_update_posted_date": "2019-07-08",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02705638"
    },
    {
      "nct_id": "NCT07025330",
      "title": "A Study of Efgartigimod in Patients With IgG4-Related Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgG4-related Disease"
      ],
      "interventions": [
        {
          "name": "Efgartigimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 5,
      "start_date": "2025-11-12",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07025330"
    },
    {
      "nct_id": "NCT04520451",
      "title": "Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin G4 Related Disease"
      ],
      "interventions": [
        {
          "name": "rilzabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Glucocorticoids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Principia Biopharma, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-08-22",
      "completion_date": "2024-10-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04520451"
    },
    {
      "nct_id": "NCT03669861",
      "title": "Safety and Efficacy of Abatacept in IgG4-Related Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgG4-related Disease"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-11-13",
      "completion_date": "2020-11-10",
      "has_results": true,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03669861"
    },
    {
      "nct_id": "NCT04918147",
      "title": "Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgG4 Related Disease",
        "IgG4-RD"
      ],
      "interventions": [
        {
          "name": "elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo for elotuzumab",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "famotidine",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-10-13",
      "completion_date": "2024-01-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04918147"
    },
    {
      "nct_id": "NCT04540497",
      "title": "A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "IgG4 Related Disease"
      ],
      "interventions": [
        {
          "name": "Inebilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2020-12-04",
      "completion_date": "2028-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-07-23T08:09:18.315Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540497"
    }
  ]
}